介素-8 预测致命的卡拉-阿扎尔:一个病例对照研究
Simone Soares Lima1,2, Débora Cavalcante Braz3, Vladimir Costa Silva4
1Department of Maternal and Child Health, Federal University of Piauí, Teresina 64049-550, Piauí, Brazil.
Tropical medicine and infectious disease
|September 26, 2025
概括
干白素-8 (IL-8) 血清水平可以预测卡拉阿扎尔患者的致命结果. 接受治疗时IL-8度升高表明患这种疾病的死亡风险较高.
科学领域:
- 免疫学 免疫学 免疫学
- 热带医学 热带医学
- 生物标志物发现发现
背景情况:
- 卡拉阿扎尔 (内脏莱什曼病) 带来了显著的死亡风险,特别是在特有地区.
- 早期识别生物标志物对于及时干预和风险分层至关重要.
- 血清细胞因子是疾病严重程度和预后的潜在指标.
研究的目的:
- 为了确定血清细胞因子概况,预测卡拉-阿扎尔患者的致命结果.
- 评估特定的细胞因子,包括IL-1β,IL-6,IL-8,IL-10,IL-12和TNF-α,作为预后生物标志物.
- 使用已识别的生物标志物建立可靠的死亡率预测值.
主要方法:
- 在48名已故的Kala-Azar患者和42名幸存者之间比较血清细胞因子水平.
- 使用流式细胞计量对细胞因子的量化.
- 统计分析包括威尔科克森等级总和测试和采用Youden指数的接收器运行特征 (ROC) 分析.
主要成果:
- 与幸存者 (中位数26.4 pg/mL;p < 0.0001) 相比,已故患者 (中位数76.5 pg/mL) 观察到显著更高的IN-8 (IL-8) 度.
- ROC分析确定IL-8的最佳切线为49.3 pg/mL,临床值为50 pg/mL.
- 一个IL-8水平≥50 pg/mL预测致命的Kala-Azar与70.8%的灵敏度和76.2%的特异性 (AUC0.75).
- 其他测试的细胞因子 (IL-1β,IL-6,IL-10,IL-12,TNF-α) 没有显著的预后价值.
结论:
- 血清IL-8水平≥50 pg/mL作为致命卡拉-阿扎尔的可靠预测指标.
- IL-8已成为一种有价值的预后生物标志物,用于识别高风险患者.
- 这一发现可以有助于早期风险分层和卡拉阿扎尔的有针对性的管理策略.
更多相关视频
08:38A Strategy for the Study of IL-9-Producing Lymphoid Cells in the Nippostrongylus brasiliensis Infection Model
Published on: March 3, 2023
1.7K
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
719
相关概念视频
Coronary Artery Disease I: Introduction
1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Hazard Ratio
756
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
756
